Of mice and men: a curious tale of disappearing plaques and tumbling stocks

Abstract

Objective:

To describe the events surrounding the recent termination of Elan Pharmaceutical's phase 2a trial of beta amyloid immunisation for Alzheimer's disease.

Conclusions:

Excessive and uncritical enthusiasm for new treatments can lead to negative clinical and financial outcomes.

Keywords

beta amyloid Elan pharmaceutical industry transgenic mouse.

Get full access to this article

View all access options for this article.

References

Schenk

, Barbour

, Dunn

Immunisation with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–177.

Games

Alzheimer-like neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523–527.

Dalton

Patent suit on Alzheimer's mouse rejected. Nature 2000; 405: 989–990.